MacroGenics reports updated Phase 1 data on MGD010
MacroGenics announced the presentation of updated data from its Phase 1 study of MGD010 at the European League Against Rheumatism Annual European Congress of Rheumatology. The Company highlighted the immunomodulatory impact of MGD010 on the response to hepatitis A vaccination in normal healthy subjects. The data demonstrate that by pharmacologically exploiting the activity of the checkpoint molecule CD32B in combination with the B-cell receptor CD79B component, a single dose administration of MGD010 at either 3 or 10 mg/kg delivers an immunomodulatory effect that counters B-cell function, the company said. There were no CTCAE grade 3 or higher adverse events related to MGD010. Consistent with prior observations, ex vivo flow cytometric analysis confirmed dose-dependent MGD010 binding to peripheral B cells without B-cell depletion, accompanied by decreased surface BCR and CD40 expression as well as a decrease in total serum IgM levels. Compared to the placebo group, reduced HAV seroconversion rates were observed in subjects treated with MGD010, with significantly lower HA-specific IgG levels. "These results provide compelling rationale for further development of this therapeutic modality for autoimmune disorders," the company remarked.